Search

Researchers at Pamela Youde Nethersole Eastern Hospital in Hong Kong reported a case of a 6-year-old Chinese boy with Juvenile Huntington Disease, a rare form of the neurodegenerative disorder. The study highlights the challenges of diagnosing Huntington Disease in children due to its atypical presentation. Early genetic confirmation and multidisciplinary care are crucial for managing patients with this condition. The research has been peer-reviewed and published in the Hong Kong Journal of Paediatrics. [Extracted from the article]

The article discusses the development of LRRK2-selective type-II kinase inhibitors for Parkinson's Disease, targeting the inactive conformation of the enzyme. These inhibitors are designed using a combinatorial chemistry approach and have shown promising results in cellular assays and structural analysis. The new compounds could provide valuable tools for studying LRRK2's function and regulation, as well as expanding potential therapeutic options for Parkinson's Disease. [Extracted from the article]

A study published in Drug Week discusses the impaired maturation of wild-type superoxide dismutase 1 (SOD1) in Parkinson's disease. The research explores the mechanisms behind the formation of SOD1 pathology in the brain and its impact on dopamine neuron health. The study introduces a novel mouse model, the SOCK mouse, to investigate the development of Parkinson-like SOD1 pathology and its effects on neurodegeneration. The findings suggest that correcting alterations to SOD1 post-translational modifications could be a potential drug target for Parkinson's disease. [Extracted from the article]

Researchers at the University of Extremadura have published new data on Parkinson's disease, highlighting the connections between neuroinflammatory processes and alterations in intestinal microbiota in the progression of the disease. The study explores the impact of neuroinflammation and gut microbiota on Parkinson's disease, emphasizing the bidirectional communication along the gut-brain axis. The research also discusses emerging therapeutic strategies targeting these pathways to potentially alter disease progression and improve the quality of life for individuals with Parkinson's disease. [Extracted from the article]

A recent study conducted at Ain Shams University in Cairo, Egypt, focused on improving the brain bioavailability of Selegiline, a monoamine oxidase B inhibitor used in the treatment of Parkinson's disease. The study introduced Rhamnosomes, lipidic vesicles decorated with lactoferrin, to actively target Selegiline to the brain. Results showed that the optimized Rhamnosomes had enhanced drug targeting efficiency and bioavailability compared to existing products, making them a promising non-invasive approach for treating Parkinson's disease. This research has been peer-reviewed and offers valuable insights into potential advancements in Parkinson's disease treatment. [Extracted from the article]

Researchers from JSS College of Pharmacy in Karnataka, India, have conducted a study on the therapeutic potential of berberine in Parkinson's disease. The study focused on how berberine could regulate cholesterol levels in the brain to improve cognitive function in Parkinson's disease. The findings suggest that berberine has the potential to mitigate cognitive impairment in Parkinson's disease by protecting hippocampal pyramidal neurons through regulating cholesterol homeostasis. This research provides valuable insights into the mechanisms underlying the beneficial effects of berberine in Parkinson's disease and its promise as a therapeutic agent for managing cognitive deficits associated with this neurodegenerative disorder. [Extracted from the article]

A research study conducted at Perugia General Hospital in Italy focused on the effects of botulinum toxin on freezing of gait in Parkinson's disease patients. Freezing of gait is a common and debilitating motor impairment in advanced stages of Parkinson's disease. The study aimed to review past research on the use of botulinum toxin in treating freezing of gait to better understand its effectiveness. The findings of the study were published in the journal Toxins, and more information can be obtained from the authors at Perugia General Hospital. [Extracted from the article]

A recent study conducted by researchers at the National Autonomous University of Mexico (UNAM) explored the role of cyclin-dependent kinase 5 (Cdk5) in striatal synaptic plasticity in a model of early Huntington's disease. The study found that Cdk5 may attenuate signaling pathways that lead neurons to increase their activity during early neurodegeneration. The research suggests that Cdk5 could play a significant role in the cellular changes associated with Huntington's disease. [Extracted from the article]

A study conducted at the Veterans Affairs Medical Center in Portland, Oregon, explored the relationship between dopamine loss, alterations in glutamate synapses, and anxiety-related behaviors in a rodent model of Parkinson's disease. The research found that dopamine loss led to increased anxiety-related behaviors, changes in glutamate synapses, and alterations in glutamate transporters in the medial prefrontal cortex. These findings suggest a potential link between dopamine loss, glutamate levels, and anxiety in Parkinson's disease. The study was peer-reviewed and published in the European Journal of Neuroscience. [Extracted from the article]

A recent study conducted in Catanzaro, Italy, focused on identifying serum diagnostic biomarkers for Progressive Supranuclear Palsy (PSP) and Parkinson's Disease (PD). The study utilized proximity elongation assay (PEA) to analyze proteins in serum samples from patients with PSP, PD, and healthy controls. The research identified five proteins that showed different levels between PSP and PD, with promising classification performance. However, caution is advised when translating proteomic findings into clinical practice, as there were discrepancies between PEA and ELISA technology. [Extracted from the article]

A recent study conducted by researchers at Nanjing Medical University focused on understanding Parkinson's disease (PD) and the potential benefits of AVE0991 in ameliorating dopaminergic neuronal damage. The study found that AVE0991 improved behavior disorders and decreased a-syn expression in mice with PD, inhibiting the apoptosis of dopaminergic neurons. The research suggests that AVE0991 targets the HOTAIRM1/miR-223-3p/a-synuclein axis to degrade a-synuclein in PD mice, showing neuroprotection in vitro. The study provides valuable insights into potential therapeutic approaches for PD. [Extracted from the article]

A recent study conducted by researchers at the University of Iowa Health Care explored the impact of dopaminergic medication on gait and balance regularity in individuals with Parkinson's disease. The study found that medication-induced improvements in Parkinson's patients may lead to increased signal consistency. The research suggests that future studies should incorporate both linear and nonlinear measures to better understand gait and balance performance in individuals with Parkinson's disease. [Extracted from the article]

A recent study from Yale University School of Medicine explores the impact of environmental enrichment on reproductive parameters in a mouse model of Parkinson's disease. The research suggests that enhanced enrichment and nutrition can improve breeding efficiency and reproductive outcomes in mice with a genetic predisposition to Parkinson's disease. This study highlights the importance of incorporating environmental enrichment to enhance reproductive parameters in mouse models of neurologic conditions. For more information, readers can access the full article in the Journal of the American Association for Laboratory Animal Science. [Extracted from the article]

A recent study conducted at Thomas Jefferson University in Philadelphia, Pennsylvania, focused on improving deep brain stimulation (DBS) programming for Parkinson's Disease. The research explored the safety and feasibility of prospective automated connectomic DBS programming, which aims to optimize stimulation parameters for better treatment outcomes. The study involved thirteen participants and found that automated connectomic programming appeared clinically safe and feasible, leading to motor improvement in patients. Further investigation is needed to refine the optimization algorithm and assess the clinical benefits in a larger cohort. [Extracted from the article]

A recent study conducted at University Hospital in Creteil, France, focused on improving gait rehabilitation in Parkinson's disease patients by introducing adaptive spatial auditory cueing (ASAC) during walking training. The study compared the effects of ASAC versus usual rhythmic auditory cueing on walking distance, speed, step length, cadence, and other parameters. Results showed that ASAC led to a 15% increase in walking distance compared to rhythmic auditory cueing, indicating potential benefits for gait relearning in Parkinson's disease. The research has been peer-reviewed and published in Revue Neurologique. [Extracted from the article]

Researchers from Zhejiang University School of Medicine in China conducted a study on Parkinson's disease, focusing on the role of Nicotinamide phosphoribosyltransferase (NAMPT) in dopaminergic neurons. The research found that the deficiency of NAMPT led to neurodegeneration and the development of Parkinson's disease in mice. The study suggests that NAD precursors could potentially protect dopaminergic neurons and offer a therapeutic approach for treating Parkinson's disease. The findings were published in the Brain Research Bulletin. [Extracted from the article]

Researchers at University Hospital in Quebec City, Canada, conducted a study on the use of 5-alpha reductase inhibitors in animal models of Parkinson's Disease. The study found that these inhibitors showed neuroprotective properties in the brain and gut dopaminergic systems, reducing dyskinesias in rodent models of PD. The research suggests that these inhibitors could potentially be repurposed to address gut dysfunction, protect brain dopamine, and inhibit dyskinesias in men with Parkinson's Disease. The study was supported by the Canadian Institutes of Health Research and has been peer-reviewed. [Extracted from the article]

A recent study conducted at the University of Turin evaluated the use of diffusion tensor image analysis along the perivascular space (DTI-ALPS) index in assessing differences between Parkinson's disease and Alzheimer's disease. The research found that the DTI-ALPS index can effectively measure the functioning of the glymphatic system in both healthy individuals and patients with these neurodegenerative disorders. The study suggests that the DTI-ALPS index has the potential to enhance clinical diagnostics and improve understanding of neurodegenerative pathologies. [Extracted from the article]

A recent study conducted at Islamic Azad University in Iran explored the effects of high-intensity interval training (HIIT) and Acetyl-L-carnitine supplementation on spatial memory in a male rat model of Parkinson's disease. The research found that the combination of HIIT and Acetyl-L-carnitine significantly improved spatial memory in rats with Parkinson's disease, suggesting potential benefits for cognitive function in this population. The study highlights the potential of exercise and nutritional interventions in enhancing brain function and ameliorating pathological changes associated with neurodegenerative disorders like Parkinson's disease. [Extracted from the article]

Researchers from University College Cork conducted a study on the inter-rater reliability of hand motor function assessment in Parkinson's disease (PD). The study involved eight clinicians independently rating tremor and bradykinesia severity in patients with PD. The research found that clinicians varied in rating video-recorded PD upper limb motor features, especially bradykinesia, but this variability could be improved somewhat with training. The study highlights the importance of standardized assessments and clinician training in accurately evaluating motor symptoms in patients with Parkinson's disease. [Extracted from the article]

Researchers from Chulalongkorn University in Bangkok, Thailand, conducted a study on the effects of art and dance therapy on Parkinson's disease (PD) patients' caregivers. The study involved group art therapy, group dance movement therapy, and co-group therapy sessions for patients and caregivers. Results showed that depression scores improved significantly in caregivers post-intervention, indicating that art and dance therapy can benefit both PD patients and their caregivers. This research was peer-reviewed and published in The Arts in Psychotherapy journal. [Extracted from the article]

Researchers at Duke University have published a study on Lewy body disease, focusing on the aggregation and fibrillization of a-synuclein, which plays a crucial role in Parkinson's disease and multiple system atrophy. The study reveals the atomic structure of mouse a-synuclein fibrils, highlighting differences in structure, hydrophobicity, and immunological responses compared to human fibrils associated with Lewy body diseases. These findings offer insights into the pathogenicity of a-synuclein and suggest a reevaluation of the use of mouse a-synuclein fibrils in diagnostic and therapeutic research. [Extracted from the article]

The article explores the immune cell distributions in the blood of healthy individuals with a high genetic risk of Parkinson's disease. Researchers used multicolor flow cytometry to analyze 92 immune cell subtypes in 442 participants and found no significant associations between polygenic risk scores for PD and immune cell subtypes. However, older individuals at increased genetic risk showed higher proportions of certain immune cells, suggesting that major alterations in immune cells may occur later in the progression of Parkinson's disease. The preprint has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Yale School of Public Health focused on Parkinson's disease, a prevalent neurodegenerative disorder. The study utilized single-nucleus transcriptomics and unbiased proteomics to analyze brain cell populations in individuals with late-stage PD. The findings highlighted distinct transcriptional changes in brain cell types, elevated brain-resident T cells, and synaptic protein down-regulation in the prefrontal cortex of PD brains. The research also compared the single-cell PD dataset with Alzheimer's disease, revealing differences in gene expression in neurons and glial cells between the two conditions. [Extracted from the article]

Researchers from the University of Alabama at Birmingham have conducted a study on Parkinson's disease, focusing on the role of disease-associated microglia (DAM) in neurodegenerative diseases. The study highlights the unique characteristics of DAM in Alzheimer's Disease and raises questions about their role in other neurodegenerative conditions like Parkinson's disease. The researchers suggest using a multi-omics model to further investigate the triggers and functions of DAM in Parkinson's disease. This study provides valuable insights into the potential heterogeneity of DAM across different neurodegenerative pathologies. [Extracted from the article]

Researchers at Taibah University have published a study on a patient with Parkinson's disease who had a de novo SCN1A missense variant. The study found that the patient did not exhibit any clinical manifestations of epilepsy, despite the known association of SCN1A variants with epilepsy-related conditions. The patient showed a positive response to carbidopa-levodopa treatment, suggesting that the SCN1A variant may be linked to Parkinson's disease features without epilepsy. [Extracted from the article]

The article discusses how the inhibition of indirect pathway activity in a mouse model of Parkinson's Disease can lead to abnormal decision-making, resembling Impulse Control Disorder (ICD) symptoms. In Parkinson's Disease, the loss of dopamine neurons disrupts the coordination of striatal direct and indirect pathway neurons, affecting motor and cognitive functions. The study found that dopamine agonists and chemogenetic inhibition of indirect pathway neurons in parkinsonian mice resulted in ICD-like behaviors, shedding light on the pathophysiology of ICD in Parkinson's Disease. [Extracted from the article]

The University of Virginia conducted a longitudinal study on Parkinson's disease psychosis (PDPsy) in patients without dementia. The research found that depressive symptoms and executive/attentional dysfunction were associated with an increased risk of PDPsy. The study enrolled 105 participants, with the prevalence of PDPsy increasing over three years from 31% to 39%. Visual illusions and hallucinations were common symptoms observed in the participants. [Extracted from the article]

The article explores the interplay between sex and disease burden in Huntington's Disease (HD) from clinical and neuroimaging perspectives. It highlights sex-related differences in symptomatology and disease progression, with females showing less pronounced striatal atrophy and cortical thinning but experiencing greater motor, cognitive, and functional decline with increasing disease burden. The study emphasizes the significance of incorporating sex-specific considerations in the clinical staging and management of HD. [Extracted from the article]

A clinical trial, NCT06676995, is investigating the potential benefits of Transcranial Pulse Stimulation (TPS) in improving symptoms associated with Parkinson's disease, such as movement problems, cognitive abilities, mood, and more. The trial aims to assess the safety, practicality, and effectiveness of TPS in enhancing the quality of life for Parkinson's patients. Previous research suggests that TPS may have positive effects on Alzheimer's disease and could be beneficial for Parkinson's as well. The trial is not yet recruiting participants and is set to conclude by September 30, 2026. [Extracted from the article]

A recent report from the School of Computer Science and Engineering delves into Parkinson's disease, a chronic neurodegenerative illness affecting the brain and central nervous system. The study emphasizes the importance of early and precise diagnosis for effective medical intervention and improved quality of life for patients. By integrating neuroimaging techniques, clinical data, and advanced computational algorithms, the research explores various modalities and datasets for Parkinson's disease detection, highlighting the potential of AI systems in providing reliable and accurate identification for prompt therapeutic treatments. [Extracted from the article]

Fosun, a prominent healthcare company, attended the 7th China International Import Expo (CIIE) to showcase cutting-edge medical devices and pharmaceuticals. At the event, Fosun highlighted the Ion Robotic Bronchoscopy system, a key diagnostic tool for early lung cancer detection. Additionally, Fosun introduced innovative treatments for neurological diseases like essential tremor and Parkinson's disease, aiming to meet unmet clinical needs. The company's participation in CIIE has facilitated the introduction of global products and the export of local innovations to benefit patients worldwide. [Extracted from the article]

The article explores the shared pathway-specific network mechanisms of dopamine and deep brain stimulation in the treatment of Parkinson's disease. It discusses how deep brain stimulation can modulate neural pathways to alleviate neurological symptoms, similar to dopaminergic drug treatment. The study combines invasive neural recordings with MRI-based connectomics to understand the mesoscale and macroscale effects of dopamine and stimulation on neural population activity and network synchrony. The findings aim to enhance the understanding of circuit mechanisms for advanced closed-loop neurostimulation therapies. [Extracted from the article]

The article discusses the potential therapeutic implications of suppressing Huntington's Disease somatic instability through transcriptional repression and direct CAG repeat binding. Various approaches, such as antisense oligonucleotides, CRISPR-Cas9 genome editing, and zinc finger transcriptional repressor proteins, were investigated in HD knock-in mice. The study suggests that DNA-targeted HTT-lowering treatments may offer advantages in addressing somatic instability in Huntington's Disease. [Extracted from the article]

Acadia Pharmaceuticals Inc. reported its financial results for the third quarter of 2024, showing $250.4 million in total revenues and a projected annual sales milestone of over $1 billion in 2025. The company's CEO, Catherine Owen Adams, expressed optimism about the future of Acadia and its potential to provide innovative therapies to patients. Acadia also launched a disease education campaign with actor Ryan Reynolds to raise awareness about Parkinson's-related hallucinations and delusions, and received marketing authorization in Canada for DAYBUE (trofinetide) for the treatment of Rett syndrome. [Extracted from the article]

A clinical trial, NCT06671600, is investigating the effects of Osteopathic Manipulative Treatment (OMT) on sleep quality in Parkinson's disease patients. Parkinsonism, often caused by Parkinson's disease, can lead to sleep disturbances, impacting quality of life and increasing health risks. OMT, a hands-on therapy, aims to improve sleep without side effects. The study will compare OMT to a light touch treatment, focusing on sleep quality, cognitive function, and daily activities, potentially offering a valuable addition to Parkinson's disease treatments. [Extracted from the article]

Researchers have submitted a patent application titled "Systems And Methods For Sensed Signal Guidance" for approval, focusing on improving lead placement and programming using evoked responses like Evoked Resonant Neural Activity (ERNA) for Deep Brain Stimulation therapy in Parkinson's Disease. The inventors aim to provide systems and methods that accommodate different desired evoked response targets based on anatomical factors and other variables. The application includes details on user-selected acceptance criteria, electrostimulation delivery, sensing circuits, user interfaces, and controllers to enhance treatment outcomes. The patent application was filed on April 25, 2024, and made available online on October 31, 2024. [Extracted from the article]

A recent study conducted at Shinshu University in Matsumoto, Japan, focused on the endoscopic evacuation of putaminal hemorrhage using the trans-middle temporal gyrus approach. The research highlighted the safety and feasibility of this approach in managing complex cases of putaminal hemorrhage that extend into the temporal lobe. By utilizing innovative techniques and equipment, the endoscopic trans-middle temporal gyrus approach allowed for effective hematoma evacuation and hemostasis without complications, showcasing its potential benefits in minimizing damage to normal brain tissue. This study was supported by the Japanese Foundation for Research and Promotion of Endoscopy and has been peer-reviewed for publication in the Journal of Neurological Surgery Part A Central European Neurosurgery. [Extracted from the article]

A recent study conducted by researchers from the Department of Radiology focused on analyzing corticospinal tract damage in acute cerebral anterior circulation infarction in the basal ganglia region using magnetic resonance imaging (MRI) diffusion tensor imaging (DTI). The study found a significant decrease in fractional anisotropy (FA) values on the ischemic side compared to the healthy side, indicating varying degrees of damage to the corticospinal tract. The researchers concluded that DTI technology can provide important clinical information for diagnosing and prognosing acute cerebral infarction by evaluating the degree of corticospinal tract injury. [Extracted from the article]

A recent study conducted at the Digestive Diseases Institute in Cleveland, Ohio, focused on the functional and postoperative outcomes of patients with Parkinson's disease and multiple sclerosis who underwent ideal pouch-anal anastomosis surgery. The research found that patients with neurological diseases may experience complications such as pouchitis and pouch dysfunction, affecting pouch emptying. Despite these challenges, the study concluded that the rate of pouch failure was similar in patients with multiple sclerosis and Parkinson's disease, demonstrating the feasibility of the surgery in these populations. The findings suggest that neurological diseases may impact pouch function, highlighting the importance of further research in this area. [Extracted from the article]

A recent study conducted by researchers at the Guangdong-Hongkong-Macau Institute of CNS Regeneration in China focused on investigating retinal abnormalities in a mouse model of Huntington's disease. The study found that the outer retina in R6/1 mice exhibited pronounced symptoms of Huntington's disease at 6 months, including neuronal loss and impaired visual function. Additionally, the research revealed that retinal pathology in these mice manifested earlier in the outer retina than in the inner retina, suggesting that the R6/1 mouse model could be valuable for studying the mechanisms underlying Huntington's disease and potential therapeutic strategies. [Extracted from the article]

Researchers from Henan University in Kaifeng, China, have conducted a study on the relationship between Type 2 diabetes mellitus (T2DM) and Parkinson's Disease (PD). The research aims to uncover the molecular mechanisms that connect T2DM and PD, highlighting shared pathways such as genetic risk factors, hyperglycemia, inflammation, and oxidative stress. This review offers insights into potential therapeutic strategies for both T2DM and PD, emphasizing the importance of understanding the overlapping molecular pathways involved in these conditions. The study was funded by various organizations, including the National Natural Science Foundation of China. [Extracted from the article]

A recent report from Pennsylvania State University highlights the connection between inhaled environmental toxins and an increased risk of dementia, including Alzheimer's disease and Parkinson's disease. The study emphasizes the impact of dementia on individuals, caregivers, society, and the economy, calling for greater visibility of this information in scientific literature and media. The research reviews olfactory processes, brain invasion by toxins, neuropathology in dementia, and considers factors like COVID-19 and wildfire pollution. This peer-reviewed study provides valuable insights into the relationship between environmental toxins and neurodegenerative diseases. [Extracted from the article]

The article discusses a study on Parkinson's disease (PD) that explores the impact of simulated microgravity on alpha-synuclein aggregation and oxidative stress in cell models. The research suggests that simulated microgravity accelerates PD-related alterations, including increased misfolded alpha-synuclein and oxidative stress, mimicking aging-related stress in PD patients. The study highlights the potential of simulated microgravity as a tool for investigating aging processes in neurodegenerative diseases. [Extracted from the article]

The article discusses the role of transposable elements (TEs) in aging brains and neurodegenerative disorders such as Huntington's Disease (HD) and Parkinson's Disease (PD). The study found significant changes in TE small RNAs in aging human brains, with a negative relationship between TE small RNAs and long RNAs. Additionally, the research suggests that TE RNAs could potentially serve as biomarkers for human brain aging and neurodegenerative disorders. The preprint has not yet been peer-reviewed, and more information can be found on biorxiv.org. [Extracted from the article]

Researchers from Peking University in China conducted a study on Parkinson's disease, focusing on the degeneration of dopaminergic neurons in the substantia nigra. Using single-cell RNA sequencing, they identified different cell clusters and found that icaritin, a flavonoid extracted from Epimedium sagittatum Maxim, showed therapeutic effects in a rat model of PD by improving interactions between cell populations and modulating various cellular processes. The study highlights the potential of icaritin as a promising therapeutic option for Parkinson's disease. [Extracted from the article]

Research from Tanta University in Egypt explores the potential benefits of using canagliflozin in combination with levodopa/carbidopa to treat Parkinson's disease. The study suggests that this combination therapy may help mitigate the effects of rotenone-induced parkinsonism in mice by targeting various pathways and mechanisms associated with the disease. The findings indicate that canagliflozin could serve as a valuable adjunct therapy to enhance the effectiveness of levodopa/carbidopa in combating the pathological effects of Parkinson's disease. [Extracted from the article]

A recent study from the International University of Catalunya in Barcelona, Spain, explores the role of inflammation in neurological disorders such as multiple sclerosis, Alzheimer's, and Parkinson's disease. The research emphasizes the potential of inflammatory biomarkers for diagnosis and treatment, highlighting recent findings on neuroinflammation mechanisms and the implications for therapeutic strategies. The study suggests that future research should focus on validating these biomarkers in larger cohorts to enhance diagnostic accuracy and therapeutic efficacy. [Extracted from the article]

A recent study conducted by Harvard University T.H. Chan School of Public Health examined the impact of air pollution on hospitalizations related to Parkinson's disease among Medicare beneficiaries nationwide. The research found that higher exposure to fine particulate matter, nitrogen dioxide, and ozone was associated with an increased rate of hospitalizations with Parkinson's disease. The study utilized various models and adjustments to analyze the data, ultimately concluding that air pollution contributes to higher rates of hospitalizations for Parkinson's disease. [Extracted from the article]

SandboxAQ has partnered with The Michael J. Fox Foundation for Parkinson's Research to accelerate the identification of compounds that activate a gene linked to Parkinson's disease. The collaboration aims to target ATP10B, a novel candidate risk gene for PD encoding a sphingolipid-transporting ATPase involved in neuronal lipid homeostasis. By leveraging innovative technology and AI simulation techniques, SandboxAQ and KU Leuven researchers are working to unlock novel treatments for Parkinson's disease. [Extracted from the article]